Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$22.26 +0.3%	$17.59	$13.40 ▼ $25.23	$3.76B	0.65	1.94 million shs	1.07 million shs
BHC Bausch Health Companies	$5.35 +4.8%	$4.82	$3.96 ▼ $9.85	$1.98B	0.28	2.56 million shs	2.20 million shs
ISEE IVERIC bio	$39.95	$38.88	$9.39 ▼ $39.99	$5.50B	1.06	3.62 million shs	N/A
RARE Ultragenyx Pharmaceutical	$37.47 -0.1%	$35.66	$29.59 ▼ $60.37	$3.54B	0.25	849,995 shs	877,583 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-0.45%	+1.00%	+27.29%	+32.38%	+49.19%
BHC Bausch Health Companies	+4.20%	+11.03%	+11.76%	-25.06%	-19.54%
ISEE IVERIC bio	0.00%	0.00%	0.00%	0.00%	0.00%
RARE Ultragenyx Pharmaceutical	+1.27%	+3.05%	+6.68%	-6.90%	-10.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.4598 of 5 stars	3.3	2.0	0.0	0.0	3.3	4.2	1.3
BHC Bausch Health Companies	4.5745 of 5 stars	2.9	5.0	0.0	4.0	2.5	1.7	1.9
ISEE IVERIC bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	3.9751 of 5 stars	3.5	1.0	0.0	3.8	2.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.69	Moderate Buy	$26.79	20.31% Upside
BHC Bausch Health Companies	1.86	Reduce	$7.42	38.76% Upside
ISEE IVERIC bio	0.00	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	2.92	Moderate Buy	$88.77	136.91% Upside

Current Analyst Ratings Breakdown

Latest BHC, RARE, ISEE, and ACAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $30.00
6/5/2025	ACAD ACADIA Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/5/2025	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Hold	$18.00 ➝ $23.00
5/28/2025	RARE Ultragenyx Pharmaceutical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
5/21/2025	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$20.00 ➝ $35.00
5/20/2025	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $24.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$28.00 ➝ $31.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $23.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$26.00 ➝ $26.00
5/19/2025	ACAD ACADIA Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$24.00 ➝ $28.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $30.00

(Data available from 6/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$996.28M	3.74	N/A	N/A	$2.63 per share	8.47
BHC Bausch Health Companies	$9.73B	0.20	$5.69 per share	0.94	($0.89) per share	-6.01
ISEE IVERIC bio	N/A	N/A	N/A	N/A	$4.43 per share	N/A
RARE Ultragenyx Pharmaceutical	$590.69M	6.00	N/A	N/A	$2.76 per share	13.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	-$61.29M	$1.37	28.82	29.29	N/A	13.83%	25.83%	14.71%	8/5/2025 (Estimated)
BHC Bausch Health Companies	-$46M	-$0.11	N/A	1.15	0.37	-0.48%	-577.82%	5.24%	7/30/2025 (Estimated)
ISEE IVERIC bio	-$185.21M	-$1.76	N/A	N/A	N/A	N/A	-57.00%	-46.15%	N/A
RARE Ultragenyx Pharmaceutical	-$569.18M	-$5.88	N/A	N/A	N/A	-101.60%	-193.80%	-38.15%	7/30/2025 (Estimated)

Latest BHC, RARE, ISEE, and ACAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
5/6/2025	Q1 2025	RARE Ultragenyx Pharmaceutical	-$1.54	-$1.57	-$0.03	-$1.57	$145.98 million	$139.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Companies	N/A	N/A	N/A	N/A	N/A
ISEE IVERIC bio	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.29	2.11
BHC Bausch Health Companies	N/A	0.86	0.62
ISEE IVERIC bio	0.20	15.53	15.53
RARE Ultragenyx Pharmaceutical	N/A	2.37	2.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
BHC Bausch Health Companies	78.65%
ISEE IVERIC bio	N/A
RARE Ultragenyx Pharmaceutical	97.67%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
BHC Bausch Health Companies	8.05%
ISEE IVERIC bio	2.70%
RARE Ultragenyx Pharmaceutical	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	119.30 million	Optionable
BHC Bausch Health Companies	19,900	370.08 million	338.06 million	Optionable
ISEE IVERIC bio	163	137.78 million	134.06 million	Optionable
RARE Ultragenyx Pharmaceutical	1,310	94.54 million	86.99 million	Optionable

BHC, RARE, ISEE, and ACAD Headlines

Recent News About These Companies

Wedge Capital Management L L P NC Buys Shares of 35,695 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

June 11 at 4:37 AM | marketbeat.com

Analysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Price Target at $88.77

June 11 at 3:01 AM | americanbankingnews.com

Research Analysts Offer Predictions for RARE FY2026 Earnings

June 10 at 8:30 AM | marketbeat.com

China's rare earth exports climb 23% in May ahead of trade talks with the U.S.

June 9 at 6:24 AM | msn.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by Brokerages

June 8 at 3:27 AM | marketbeat.com

Ultragenyx Pharmaceutical reports Q1 earnings

June 6, 2025 | pressdemocrat.com

Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?

June 5, 2025 | zacks.com

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference

June 3, 2025 | globenewswire.com

Mackenzie Financial Corp Acquires 11,825 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

June 2, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

June 1, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

June 1, 2025 | marketbeat.com

FY2025 Earnings Forecast for RARE Issued By William Blair

June 1, 2025 | americanbankingnews.com

Equities Analysts Offer Predictions for RARE FY2025 Earnings

May 31, 2025 | marketbeat.com

William Blair Begins Coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE)

May 29, 2025 | marketbeat.com

William Blair Initiates Coverage of Ultragenyx Pharmaceutical (RARE) with Outperform Recommendation

May 29, 2025 | msn.com

Squarepoint Ops LLC Purchases Shares of 87,989 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

May 28, 2025 | marketbeat.com

Ultragenyx’s SWOT analysis: rare disease biotech stock poised for growth

May 26, 2025 | investing.com

Twinbeech Capital LP Raises Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

May 24, 2025 | marketbeat.com

Two Sigma Investments LP Has $25.87 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

May 24, 2025 | marketbeat.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by Frazier Life Sciences Management L.P.

May 23, 2025 | marketbeat.com

Bank of America Corp DE Has $16.34 Million Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

May 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
3 Stocks Getting Rare Double Upgrades From Analysts
By Chris Markoch | June 6, 2025
View 3 Stocks Getting Rare Double Upgrades From Analysts
Keep Your EYE on This Stock, It Just Got a Rare Double Upgrade
By Sam Quirke | May 15, 2025
View Keep Your EYE on This Stock, It Just Got a Rare Double Upgrade
Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal
By Sam Quirke | June 11, 2025
View Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal

BHC, RARE, ISEE, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$22.26 +0.06 (+0.29%)

As of 03:57 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Bausch Health Companies NYSE:BHC

$5.34 +0.25 (+4.80%)

As of 03:57 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

IVERIC bio NASDAQ:ISEE

IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.

Ultragenyx Pharmaceutical NASDAQ:RARE

$37.47 -0.04 (-0.11%)

As of 03:57 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time